{"organizations": [], "uuid": "502a4dc0eed04348c7aba4f5d98443dcc16c37af", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-arrowhead-receives-regulatory-clea/brief-arrowhead-receives-regulatory-clearance-to-begin-phase-1-2-study-of-aro-hbv-for-treatment-of-hepatitis-b-idUSFWN1Q510H", "country": "US", "domain_rank": 408, "title": "BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-15T14:35:00.000+02:00", "replies_count": 0, "uuid": "502a4dc0eed04348c7aba4f5d98443dcc16c37af"}, "author": "", "url": "https://www.reuters.com/article/brief-arrowhead-receives-regulatory-clea/brief-arrowhead-receives-regulatory-clearance-to-begin-phase-1-2-study-of-aro-hbv-for-treatment-of-hepatitis-b-idUSFWN1Q510H", "ord_in_thread": 0, "title": "BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-arrowhead receives regulatory clearance t", "sentiment": "negative"}, {"name": "treatment of hepatitis b reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "arrowhead pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 15, 2018 / 12:38 PM / Updated 5 minutes ago BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B Reuters Staff 1 Min Read Feb 15 (Reuters) - Arrowhead Pharmaceuticals Inc: * ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-15T14:35:00.000+02:00", "crawled": "2018-02-15T14:54:49.004+02:00", "highlightTitle": ""}